

17. ELN Symposium with 20. KNL Symposium

Congress Center Rosengarten, Mannheim, September 7, 2021, 8:00-20:00

	Mahler 1	Chairs/Contributors
8:00 - 9:30	Session 1 WP4 CML EURO SKI Final Commentary on the basis of 2nd TFR with new approaches Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM) Which patients with CML in CP may benefit from third line TKI? -Data from a multicenter observational study in St. Petersburg and the Leningrad region European CML Blast Crisis registry Clonal hierarchy in CML: a HARMONY PLUS project. Covid-19 and CML	F. Guilhot, A. Hochhaus, L. Stenke M. Pfirrmann M. Mauro F. Pane E. Lomaia A. Brioli T. Ernst M. Mauro
9:30 - 9:45	Coffee Break	
9:45 - 11:15	Session 2: WP5 AML Update renewal ELN MRD recommendations <ul style="list-style-type: none"> - Molecular - Flow - Clinical Update ELN recommendation unfit AML patients Collaboration with EHA	G. Ossenkoppele, C. Thiede C. Thiede J. Cloos M. Heuser L. Maurillo K. Döhner
11:15 - 11:30	Break	
11:30 - 13:00	Session 3: HARMONY/HARMONY PLUS	J.M. Hernandez, L. Bullinger
10'	Welcome and Update HARMONY	J.M. Hernández
20'	- Results of Delphi surveys for COS Definition	K. Lang
20'	- Results of the research project on CLL HARMONY PLUS	L. Scarfò
20'	- The data we need from you in HARMONY / HARMONY PLUS & the road ahead to make them useful for us and affordable for you.	G. Sanz
20'	Discussion and concluding remarks	L. Bullinger
13:00 - 14:00	Lunch	
16:00 - 17:00	General Assembly and Summary reports	R. Hehlmann, D. Niederwieser
15'	General Assembly	R.Hehlmann
5'	WP4 (CML)	A. Hochhaus
5'	WP5 (AML)	G. Ossenkoppele
5'	HARMONY	J. Hernandez
5'	WP6 (ALL)	D. Hoelzer
5'	WP7 (CLL)	A. Rawstron

5'	WP9 (MPN)	M. Griesshammer
5'	WP10 (Immunophenotyping)	M. Béné
5'	WP12 (MRD, NGS)	T. Haferlach
5'	WP14 (Transplantation)	D. Niederwieser
17:00 - 17:30	Break with Group photo	
17:30 - 18:00	ELN Merit Awards	R. Hehlmann
5'	Francois Guilhot	
5'	Andrzej Hellmann	
5'	Fabrizio Pane	
5'	Jerzy Holowiecki (in absentia)	
5'	Sante Tura (in absentia)	
18:00 - 20:00	Session 4: Keynote lectures and special lecture	R. Hehlmann, D. Hoelzer
20'	Genetic homogeneity of populations in central Europe as determined by tissue typing	W. Jędrzejczak
20'	The HARMONY Data Platform	M. van Speybroeck
20'	Using the HARMONY data platform to answer research questions in the field of AML	L. Bullinger
30'	Major achievements within the MDS-RIGHT project	T. de Witte
20'	Special lecture: The Corona vaccination program in Israel	M. Mittelman
20:00	Working dinner in the foyer	
	Mahler 2	Chairs/Contributors
8:00 - 9:30	Session 5: WP6 ALL	D. Hoelzer, S. Chiaretti
	Ponatinib for the treatment of Ph-like ALL, from bench to bedside	S. Chiaretti
	Ph+ ALL: clinical results of changing TKI if no CMR	O. Gavrulina
	Role of nested PCR for BCR-ABL1 detection during therapy	F. Lang
	Treatment of Elderly ALL patients focusing on Immunotherapy	D. Hoelzer
	Venetoclax and HMA in R/R T-ALL	G. Isinova
	Chemo-free approach for newly diagnosed Ph+ ALL	S. Chiaretti
	The Moscow ALL Studies	E. Parovichnikova
9:30 - 9:45	Coffee Break	
9.45 – 11.15	Session 6: WP10 Immunophenotyping	M.C. Béné, G. Zini
	Update on the virtual slide review in hematological malignancies	G. Zini
	Update on the WP10 morphology faculty	G. Zini
	A new exciting new marker for T-lineage proliferations	I. Marinov
	Update on unsupervised flow cytometry analysis	M.C. Béné
	Update on IVDR	M.C. Béné
11:15 - 11:30	Break	
11:30 - 13:00	Session 7: WP9 MPN	T. Barbui
	New data on Second Wave of COVID-19 in MPN (ELN study)	T. Barbui
	DOACs in MPN. The need for a clinical trial.	M. Griesshammer
	Should we treat PV irrespectively of the thrombotic risk (ELN recommendations)?	M. Marchetti
13:00 - 14:00	Lunch	

14:00 - 15:30	Session 8: WP7 CLL Forum on MRD in CLL	A. Rawstron, L. Scarfò
15'	ERIC overview	L. Scarfò
30'	ERIC flow cytometry approach -	A. Rawstron
30'	Discussion on possible updates of the recommendations	All
15'	Summary and future plans towards revised recommendations	A. Rawstron, L. Scarfò

Mahler 3

Chairs/Contributors

8:00 - 9:30	Session 9: WP12/13 MRD/NGS Biological impact and synthetic lethal therapeutic vulnerabilities of del(11q) and concurrent gene mutations in CLL New approaches to MRD by NGS: ELN guidelines 2021 Panel, Exome, WGS or WTS in routine?	T. Haferlach, C. Thiede M. Quijada-Álamo M. Heuser N. Nadarajah
--------------------	---	---

9:30 - 9:45 Coffee Break

9:45 - 11:15	Session 10: WP14 Transplantation Reports: - Worldwide HSCT published in Haematologica - Role of HSCT in the treatment of AML published in Annals of Hematology - AML intergroup study (manuscript in preparation) - HCT-CT (Evaluation if available) New projects: - GvHD Platform, GvHD App - Waustim - AML Worldwide (incidence ans HCT) - AI and HCT HARMONY and WP 14 Allogeneic immune therapy in the framework of HCT Relapse and HSCT. Are we making progress?	T. Ruutu, D. Niederwieser, W. Jędrzejczak D. Niederwieser D. Neumann L. Garderet TBC D. Niederwieser D. Neumann D. Niederwieser H.-J. Kolb D. Niederwieser
---------------------	---	---

13:00 - 14:00 Lunch

14:00 - 15:30	Session 11: WP17 Open Statistical Session Everybody can attend and ask statistical questions which will be answered on the spot. Questions submitted in advance to <afi@ibe.med.uni-muenchen.de> are encouraged.	M. Pfirrmann
----------------------	---	---------------------

